The main risk factors for benign prostatic hyperplasia include patient age, hormonal changes (absolute or relative androgen paucity), sexual dysfunction, overweight, social and geographical conditions, reduced immune defense, disruption of the blood and lymph flow in the pelvic organs, infections. Chronic prostatitis is often combined with urethritis, vesiculitis, or prostate adenoma. Modern researches suggest an important relationship between chronic prostatitis and benign prostatic hyperplasia. The popularity of prostate protectors of natural origin is due to their complex effect on various pathogenetic links of benign prostatic hyperplasia, sufficient effectiveness with minimal risk of adverse reactions, high patient confidence, good tolerability, favorable pharmacoeconomic profile. Material and methods. Benign prostatic hyperplasia was caused by intraperitoneal administration of sulpiride (Eglonil) at a dose of 40 mg / kg of animal body weight during 30 days. Results and discussion. At the same time, hyperplasia of the lateral parts of the prostate gland developed and this correlated with similar pathological changes in the prostate gland in humans. The model of benign prostatic hyperplasia is associated with impaired testosterone synthesis in the testes due to insufficient prostate gland function, an increase level of prolactin and estradiol, which provokes proliferative changes in the organ. Benign prostatic hyperplasia, which was caused by intraperitoneal administration of sulpiride for 30 days, led to disruption of the functioning of the prostate gland, which was characterized by a significant decrease of the animals androgenic saturation, namely a decrease in the mass of the prostate gland, an increase in the prostate-specific enzyme and a decrease in serum testosterone, as well as a decrease in the content of fructose in the seminal vesicles. Chondroitin sulfate and Chondroitin sulfate+Tribestan medicines have prostatoprotective properties, in condition of the sulpiride-induced model of benign prostatic hyperplasia, and by the effectiveness of the action exceed the reference medicine Prostaplant forte. Conclusions. Using of Tribestan and "Bioglobin-U", the androgenic saturation of the organism and the functioning of the reproductive system of male ratsgradually was improved, and according to their effectiveness, they didn't exceed the effect of the reference drug Prostaplant Forte.
Keywords: chronic prostatitis, benign prostatic hyperplasia, hormonal status, Chondroitin sulfate, placenta
Full text: PDF (Ukr) 685K